Evidence map›Paper›PMID 30531955›Full record

SynthesisBone marrow transplantation2019

Non-GVHD ocular complications after hematopoietic cell transplantation: expert review from the Late Effects and Quality of Life Working Committee of the CIBMTR and Transplant Complications Working Party of the EBMT.

Yoshihiro Inamoto, Igor Petriček, Linda Burns, Saurabh Chhabra, Zack DeFilipp, Peiman Hematti, Alicia Rovó, Raquel Schears, Ami Shah, Vaibhav Agrawal and 39 more

Erratum issuedOpen access · greenAbstract readSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Bone marrow transplantation, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 11 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 1 pooled it
2.2field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 1 synthesis or guideline pooled it, 22 citations in OpenAlex.

  1. Guideline
  2. Article
  3. Review
  4. Review
  5. Review
  6. [Chinese expert consensus on ocular chronic graft-versus-host disease (2023)].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2023
    Article
  7. Article
  8. Review
  9. Article
  10. [Maculopathy in sickle cell disease].Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft · 2021
    Review
  11. Ocular surface system alterations in ocular graft-versus-host disease: all the pieces of the complex puzzle.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2019
    Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

49 authors at 20 institutions in 10 countries.

Yoshihiro Inamoto *Department of Hematopoietic Stem Cell Transplantation, National Cancer Center Hospital, Tokyo, Japan. yinamoto@ncc.go.jp.
Igor Petriček *Department of Ophthalmology, University Clinical Hospital Zagreb, Zagreb, Croatia.
Linda BurnsCIBMTR(Center for International Blood and Marrow Transplant Research), National Marrow Donor Program/Be The Match, Minneapolis, MN, USA.
Saurabh ChhabraMedical College of Wisconsin, Milwaukee, WI, USA.
Zack DeFilippBlood and Marrow Transplant Program, Massachusetts General Hospital, Boston, MA, USA.
Peiman HemattiDivision of Hematology/Oncology/Bone Marrow Transplantation, Department of Medicine, University of Wisconsin Hospital and Clinics, Madison, WI, USA.
Alicia RovóUniversitatsspital Bern, Bern, Switzerland.
Raquel SchearsMayo Clinic Rochester, Rochester, MN, USA.
Ami ShahDivision of Stem Cell Transplantation and Regenerative Medicine, Lucille Packard Children's Hospital, Stanford School of Medicine, Palo Alto, CA, USA.
Vaibhav AgrawalIndiana University Simon Cancer Center, Indianapolis, IN, USA.
Aisha Al-KhinjiUniversity of California, San Francisco, CA, USA.
Ibrahim AhmedDepartment of Hematology Oncology and Bone Marrow Transplantation, The Children's Mercy Hospitals and Clinics, Kansas City, MO, USA.
Asim AliSt. Louis Medical Clinic, St. Louis, MO, USA.
Mahmoud AljurfDepartment of Oncology, King Faisal Specialist Hospital Center & Research, Riyadh, Saudi Arabia.
Hassan AlkhateebMayo Clinic Rochester, Rochester, MN, USA.
Amer BeitinjanehDivision of Pediatrics Hematology, Children's Hospital of Orange County, Orange, CA, USA.
Neel BhattMedical College of Wisconsin, Milwaukee, WI, USA.
Dave BuchbinderDivision of Pediatrics Hematology, Children's Hospital of Orange County, Orange, CA, USA.
Michael ByrneVanderbilt University Medical Center, Nashville, TN, USA.
Natalie CallanderUniversity of Wisconsin Carbone Cancer Center, Madison, WI, USA.
Kristina FahnehjelmDepartment of Clinical Neuroscience, Karolinska Institutet, St. Erik Eye Hospital, Stockholm, Sweden.
Nosha FarhadfarShands Healthcare & University of Florida, Gainsville, FL, USA.
Robert Peter GaleHematology Research Centre, Division of Experimental Medicine, Department of Medicine, Imperial College London, London, United Kingdom.ORCID http://orcid.org/0000-0002-9156-1676
Siddhartha GangulyDivision of Hematological Malignancy and Cellular Therapeutics, University of Kansas Health System, Kansas City, KS, USA.
Gerhard C HildebrandtMarkey Cancer Center, University of Kentucky, Lexington, KY, USA.
Erich HornShands Healthcare & University of Florida, Gainsville, FL, USA.
Ann JakubowskiDivision of Hematologic Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Rammurti T KambleDivision of Hematology and Oncology, Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, TX, USA.
Jason LawTufts Medical Center, Boston, MA, USA.
Catherine LeeUtah Blood and Marrow Transplant Program Huntsman Cancer Institute, University of Utaah, Salt Lake City, UT, USA.
Sunita NathanRush University Medical Center, Chicago, IL, USA.
Olaf PenackDept. of Internal Medicine, Div. Haematology & Oncology, Charité University Medicine, Campus Rudolf Virchow, Berlin, Germany.
Ravi PingaliHouston Methodist Hospital, Houston, TX, USA.
Pinki PrasadChildren's Hospital, New Orleans, LA, USA.
Drazen PulanicDivision of Hematology, Department of Internal Medicine, University Hospital Center Zagreb, Zagreb, Croatia.
Seth RotzCincinnati Children's Hospital Medical Center, Cincinnati, OH, USA.
Aditya ShreenivasDivision of Hematology and Oncology, Mount Sinai Hospital, New York, NY, USA.
Amir SteinbergDivision of Hematology and Oncology, Mount Sinai Hospital, New York, NY, USA.
Khalid TabbaraThe School of Medicine, The Wilmer Ophthalmological Institute of The Johns Hopkins University, Baltimore, MD, USA.
André TichelliUniversity Hospital Basel, Basel, Switzerland.
Baldeep WirkDivision of Bone Marrow Transplant, Seattle Cancer Care Alliance, Seattle, WA, USA.
Jean YaredBlood & Marrow Transplantation Program, Division of Hematology/Oncology, Department of Medicine, Greenebaum Cancer Center, University of Maryland, Baltimore, MD, USA.
Grzegorz W BasakMedical University of Warsaw, Warsaw, Poland.ORCID http://orcid.org/0000-0003-3858-8180
Minoo BattiwallaHematology Branch, Sarah Cannon BMT Program, Nashville, TN, USA.
Rafael DuarteUniversity Hospital Puerta de Hierro, Madrid, Spain.
Bipin N SavaniDivision of Hematology/Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA.
Mary E D FlowersClinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Bronwen E ShawCIBMTR (Center for International Blood and Marrow Transplant Program), Department of Medicine, Medical College of Wisconsin, Milwaukee, WI, USA.
Nuria Valdés-Sanz *Department of Ophthalmology, Hospital Universitario Puerta de Hierro, Madrid, Spain.
Medical College of Wisconsin · USChildren's Hospital of Orange County · USHospital Universitario Puerta de Hierro Majadahonda · ESMayo Clinic · USMount Sinai Hospital · USUniversity Hospital Centre Zagreb · HRUniversity of Florida Health · USVanderbilt University Medical Center · USBaylor College of Medicine · USCharité - Universitätsmedizin Berlin · DEChildren's Hospital of New Orleans · USChildren's Mercy Hospital · USCincinnati Children's Hospital Medical Center · USFred Hutch Cancer Center · USHuntsman Cancer Institute · USImperial College London · GBIndiana University Health · USJohns Hopkins University · USKarolinska Institutet · SEKing Faisal Specialist Hospital & Research Centre · SA

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4M
Data Resource for Analyzing Blood &Marrow TransplantsU24CA076518 · NCI · MEDICAL COLLEGE OF WISCONSIN · PI Amy M Moskop, Bronwen Shaw · 1998 to 2026
$105.2M
Easy-to-read Informed Consent for HCT Clinical TrialsU10HL069294 · NHLBI · MEDICAL COLLEGE OF WISCONSIN · PI HOROWITZ, MARY MARESCA · 2011 to 2016
$43.8M
NCI NIH HHS P30 CA008748NCI NIH HHS U24 CA076518NHLBI NIH HHS U10 HL069294
6 · The paper itself

Abstract

Non-graft-vs.-host disease (non-GVHD) ocular complications are generally uncommon after hematopoietic cell transplantation (HCT), but can cause prolonged morbidity affecting activities of daily living and quality of life. Here we provide an expert review of non-GVHD ocular complications in a collaboration between transplant physicians and ophthalmologists through the Late Effects and Quality of Life Working Committee of the Center for International Blood and Marrow Transplant Research and the Transplant Complications Working Party of the European Society of Blood and Marrow Transplantation. Complications discussed in this review include cataracts, glaucoma, ocular infections, ocular involvement with malignancy, ischemic microvascular retinopathy, central retinal vein occlusion, retinal hemorrhage, retinal detachment, and ocular toxicities associated with medications. We have summarized incidence, risk factors, screening, prevention and treatment of individual complicastions and generated evidence-based recommendations. Baseline ocular evaluation before HCT should be considered in all patients who undergo HCT. Follow-up evaluations should be considered according to clinical symptoms, signs and risk factors. Better preventive strategies and treatments remain to be investigated for individual ocular complications after HCT. Both transplant physicians and ophthalmologists should be knowledgeable of non-GVHD ocular complications and provide comprehensive collaborative team care.

Indexed as

Activities of Daily LivingEye DiseasesHematopoietic Stem Cell TransplantationQuality of LifeFemaleHumansMaleTransplantation, Homologous

Identifiers

PMID30531955
PMCPMC6497536
OpenAlexW2904561279

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.